Hayashida Ken-Ichiro, DeGoes Sophia, Curry Regina, Eisenach James C
Department of Anesthesiology and Center for Study of Pharmacologic Plasticity in the Presence of Pain, Wake Forest University School of Medicine, North Carolina 27157-1009, USA.
Anesthesiology. 2007 Mar;106(3):557-62. doi: 10.1097/00000542-200703000-00021.
Gabapentin has been reported to inhibit various acute and chronic pain conditions in animals and humans. Although the efficacy of gabapentin depends on the alpha2delta subunit of voltage-gated calcium channels, its analgesic mechanisms in vivo are still unknown. Here, the authors tested the role of spinal noradrenergic inhibition in gabapentin's analgesia for postoperative pain.
Gabapentin was administered orally and intracerebroventricularly to rats on the day after paw incision, and withdrawal threshold to paw pressure was measured. The authors also measured cerebrospinal fluid concentration of norepinephrine and postoperative morphine use after surgery in patients who received oral placebo or gabapentin.
Both oral and intracerebroventricular gabapentin attenuated postoperative hypersensitivity in rats in a dose-dependent manner. This effect of gabapentin was blocked by intrathecal administration of the alpha2-adrenergic receptor antagonist idazoxan and the G protein-coupled inwardly rectifying potassium channel antagonist tertiapin-Q, but not by atropine. In humans, preoperative gabapentin, 1,200 mg, significantly increased norepinephrine concentration in cerebrospinal fluid and decreased morphine requirements.
These data suggest that gabapentin activates the descending noradrenergic system and induces spinal norepinephrine release, which produces analgesia via spinal alpha2-adrenoceptor stimulation, followed by activation of G protein-coupled inwardly rectifying potassium channels. The authors' clinical data suggest that gabapentin activates the descending noradrenergic system after preoperative oral administration at the time of surgery. These data support a central mechanism of oral gabapentin to reduce postoperative pain and suggest that this effect could be magnified by treatments that augment the effect of norepinephrine release.
据报道,加巴喷丁可抑制动物和人类的各种急慢性疼痛状况。尽管加巴喷丁的疗效取决于电压门控钙通道的α2δ亚基,但其体内镇痛机制仍不清楚。在此,作者测试了脊髓去甲肾上腺素能抑制在加巴喷丁对术后疼痛镇痛作用中的作用。
在大鼠 paw 切口后一天口服和脑室内给予加巴喷丁,并测量 paw 压力的撤药阈值。作者还测量了接受口服安慰剂或加巴喷丁的患者术后脑脊液中去甲肾上腺素的浓度和术后吗啡的使用情况。
口服和脑室内给予加巴喷丁均以剂量依赖的方式减轻了大鼠术后的超敏反应。加巴喷丁的这种作用被鞘内注射α2 - 肾上腺素能受体拮抗剂咪唑克生和 G 蛋白偶联内向整流钾通道拮抗剂替尔吡嗪 - Q 阻断,但未被阿托品阻断。在人类中,术前给予 1200 mg 加巴喷丁可显著提高脑脊液中去甲肾上腺素的浓度并降低吗啡需求量。
这些数据表明,加巴喷丁激活下行去甲肾上腺素能系统并诱导脊髓去甲肾上腺素释放,通过脊髓α2 - 肾上腺素能受体刺激产生镇痛作用,随后激活 G 蛋白偶联内向整流钾通道。作者的临床数据表明,术前口服加巴喷丁在手术时激活了下行去甲肾上腺素能系统。这些数据支持口服加巴喷丁减轻术后疼痛的中枢机制,并表明这种作用可通过增强去甲肾上腺素释放作用的治疗方法放大。